Pluvicto (lutetium Lu 177 vipivotide tetraxetan) is a medicine that is used to treat prostate cancer in adults. Pluvicto may be used to treat PSMA-positive prostate cancer that has spread to other ...

The percentage of prostate cancer patients with positive lymph nodes increased from 2.4% in 2010 to 4.7% in 2014. The following article is part of conference coverage from the 2018 American Urological ...

Gozetotide is a drug for diagnostic application in adults with prostate cancer. It is currently the only diagnostic agent that recognizes PSMA-positive prostate cancer and can therefore identify ...

Study findings have implications for biopsy-free radical prostatectomy. Combining PSMA-PET and mpMRI results to diagnose clinically significant prostate cancer while excluding benign prostatic ...

A PSA of 127 indicated a high probability of prostate cancer, leading to immediate Lupron ADT therapy and radiation treatment ...

Radiotherapy, a standard of care treatment for localized prostate cancer includes, has shown remarkable success. This procedure, involving the application of external high-energy radiation to kill ...

Prostate cancer is one of the leading causes of cancer deaths globally. It only affects men, and the risk of developing the disease increases with age. Despite being treatable when detected early, it ...

Researchers identify APOC1 and NOP16 as promising prostate cancer biomarkers that could aid early diagnosis. Learn more about ...